Active surveillance for prostate cancer: A narrative review of clinical guidelines

Nature Reviews Urology

Volumn 13, Issue 3, 2016, Pages 151-167

  Bruinsma, Sophie M ^a   Bangma, Chris H ^a   Carroll, Peter R ^b   Leapman, Michael S ^b   Rannikko, Antti ^c   Petrides, Neophytos ^d   Weerakoon, Mahesha ^e   Bokhorst, Leonard P ^a   Roobol, Monique J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e AUSTIN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER STAGING; CLINICAL DECISION MAKING; CLINICAL PRACTICE; DIGITAL RECTAL EXAMINATION; DISEASE CLASSIFICATION; EVIDENCE BASED PRACTICE; GLEASON SCORE; HIGH RISK POPULATION; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; REVIEW; TUMOR BIOPSY; TUMOR GROWTH; TUMOR VOLUME; WATCHFUL WAITING; BLOOD; CANCER GRADING; MALE; PROCEDURES; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTOR; STANDARDS;

DIGITAL RECTAL EXAMINATION; HUMANS; MALE; NEOPLASM GRADING; PRACTICE GUIDELINES AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84960121130     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2015.313     Document Type: Review

References (53)

1. Center, M. M., et al. International variation in prostate cancer incidence and mortality rates. Eur. Urol. 61, 1079-1092 (2012
2. Kim, T. H., et al. Pathological upgrading and upstaging of patients eligible for active surveillance according to currently used protocols. Int. J. Urol. 21, 377-381 (2013
3. Schroder, F. H., et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow up. Lancet 384, 2027-2035 (2014
4. Duffy, M. J. PSA in screening for prostate cancer: more good than harm or more harm than good?. Adv. Clin. Chem. 66, 1-23 (2014
5. Stenman, U. H., et al. Prognostic value of serum markers for prostate cancer. Scand. J. Urol. Nephrol. Suppl. 216, 64-81 (2005
6. Hugosson, J. & Carlsson, S. Overdetection in screening for prostate cancer. Curr. Opin. Urol. 24, 256-263 (2014
7. Bul, M., et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur. Urol. 63, 597-603 (2013
8. Klotz, L. Active surveillance for prostate cancer: patient selection and management. Curr. Oncol. 17, S11-S17 (2010
9. Ip, S., et al. An evidence review of active surveillance in men with localized prostate cancer. Evid. Rep. Technol. Assess. (Full Rep.) 204, 1-341 (2011
10. Cancer Care Nova Scotia (CCNS). Guidelines for the management of prostate cancer. [online], http://www.cancercare.ns.ca/sitecc/media/cancercare/ProstateGuidelinesFullVersion2006(1).pdf (2006
11. The National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Prostate cancer. [online], http://www.tri-kobe.org/nccn/guideline/urological/english/prostate.pdf (2014
12. The National Institute for Health and Clinical Excellence (NICE). Prostate cancer: diagnosis and management. [online], https://www.nice.org.uk/guidance/cg175 (2014
13. American Urological Association (AUA). Guideline for the management of clinically localized prostate cancer: 2007 update. [online], http://www.auanet.org/common/pdf/education/clinical-guidance/Prostate-Cancer.pdf (2007
14. European Association of Urology (EAU). Guidelines on prostate cancer. [online], http://uroweb.org/guideline/prostate-cancer/(2014
15. German Society of Urology (GSU). Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. Urologenportal [online], https://www.urologenportal.de/fileadmin/MDB/PDF/konsultationsfassung-leitlinie-prostatakarzinom.pdf (in German) (2014
16. Dutch Urological Association (DUA). Richtlijn prostaatcarcinoom. Richtlijnendatabase [online], http://richtlijnendatabase.nl/richtlijn/prostaatcarcinoom/algemeen.html (in Dutch) (2014
17. Belgian Healthcare Knowledge Centre (KCE). A national clinical practice guideline on the management of localised prostate cancer. [online], http://kce.fgov.be/sites/default/files/page-documents/KCE-194C- prostate-cancer-0.pdf (2013
18. South East Scotland Cancer Network (SCAN). SCAN guideline for active surveillance (deferred radical treatment) of early, low-risk, prostate cancer. [online], http://www.scan.scot.nhs.uk/Documents/SCAN%20 Protocol%20for%20Active%20Surveillance%20 of%20Early%20Prostate%20Cancer%20-%20 17072009.pdf (2015
19. Aragon Institute of Health Sciences (I+CS). Clinical practice guideline for prostate cancer treatment. Biblioteca De Guias del Practica Clinica del Systema Nacional De Salud [online], http://www.guiasalud.es/GPC/GPC-431-Prostate-Ca-ICS-compl-en.pdf (2008
20. Alberta Health Services (AHS). Alberta Health Services clinical practice guideline: prostate cancer. [online], http://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-gu004-prostate.pdf (2014
21. Singapore Ministry of Health (NCCS). Guidelines on Management of Prostate Cancer. Annals Academy of Medicine, Singapore [online], http://www.annals.edu.sg/pdf/42VolNo4Apr2013/V42N4p190.pdf (2013
22. Prostate Cancer Taskforce (PCT). Diagnosis and management of prostate cancer in New Zealand men: recommendations from the Prostate Cancer Taskforce. The New Zealand Ministry of Health [online], http://www.prostate.org.nz/documents/diagnosis-management-prostate-cancer-nz-men-(3).pdf (2013
23. The Finnish Medical Society Duodecim (FCCG). Prostate cancer (Eturauhassyöpä). SCAN [online], http://www.kaypahoito.fi/web/kh/suositukset/suositus?id=hoi11060 (in Finnish) (2014
24. Cancer Care Ontario (CCO) Evidence Based Guideline Quality Initiative. Active surveillance for the management of localized prostate cancer: guideline recommendations. Can. Urol. Assoc. J. 9, 171-178 (2015
25. Prostate Cancer Foundation of Australia and Cancer Council Australia PSA Testing Guidelines Expert Advisory Panel. Draft clinical practice guidelines PSA Testing and Early Management of Test-Detected Prostate Cancer. Cancer Council Australia [online], http://wiki.cancer.org.au/australiawiki/index.php?oldid=106555 (2015
26. AGREE Next Steps Consortium. The AGREE II Instrument [Electronic version] 2009. The Agree Enterpise [online], http://www.agreetrust.org/wp-content/uploads/2013/10/AGREE-II-Users-Manual-and-23-item-Instrument-2009-UPDATE-2013.pdf (2013
27. Joosen, M. C., et al. An international comparison of occupational health guidelines for the management of mental disorders and stress-related psychological symptoms. Occup. Environ. Med. 72, 313-322 (2015
28. Memorial Sloan Kettering Cancer Center. Prediction tools: prostate cancer. [online], https://www.mskcc.org/nomograms/prostate (2015
29. Dallera, M. A., et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 112, 1650-1659 (2008
30. Welty, C. J., et al. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. J. Urol. 193, 807-811 (2015
31. Tosoian, J. J., et al. Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. J. Clin. Oncol. 33, 3379-3385 (2015
32. Klotz, L., et al. Long-term follow up of a large active surveillance cohort of patients with prostate cancer. J. Clin. Oncol. 33, 272-277 (2015
33. Lund, L., Svolgaard, N. & Poulsen, M. H. Prostate cancer: a review of active surveillance. Res. Rep. Urol. 6, 107-112 (2014
34. Azmi, A., et al. Active surveillance for low-risk prostate cancer: diversity of practice across Europe. Ir. J. Med. Sci. 184, 305-311 (2014
35. Kweldam, C. F., Wildhagen, M. F., Bangma, C. H. & Van Leenders, G. J. Disease-specific death and metastasis do not occur in patients with Gleason score =6 at radical prostatectomy. BJU Int. 116, 230-235 (2015
36. Payer, L. P. Medicine Culture: Varieties of treatment in the United States, England, West Germany, and France (Henry Holt and Company, 1989
37. Welch, H. G. & Albertsen, P. C. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J. Natl Cancer Inst. 101, 1325-1329 (2009
38. Xu, J., Neale, A. V., Dailey, R. K., Eggly, S. & Schwartz, K. L. Patient perspective on watchful waiting/active surveillance for localized prostate cancer. J. Am. Board Fam. Med. 25, 763-770 (2012
39. McVey, G. P., et al. Initial management of low-risk localized prostate cancer in the UK: analysis of the British Association of Urological Surgeons Cancer Registry. BJU Int. 106, 1161-1164 (2010
40. Cooperberg, M. R., Broering, J. M. & Carroll, P. R. Time trends and local variation in primary treatment of localized prostate cancer. J. Clin. Oncol. 28, 1117-1123 (2010
41. Van den Bergh, R. C., et al. Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review. Eur. Urol. 65, 1023-1031 (2014
42. Loeb, S., et al. Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification. Eur. Urol. 67, 619-626 (2015
43. Klein, E. A., et al. A 17 gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur. Urol. 66, 550-560 (2014
44. Sartori, D. A. & Chan, D. W. Biomarkers in prostate cancer: whats new?. Curr. Opin. Oncol. 26, 259-264 (2014
45. Parekh, D. J., et al. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur. Urol. 68, 464-470 (2015
46. Schoots, I. G., et al. Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review. Eur. Urol. 67, 627-636 (2015
47. Sankineni, S., Osman, M. & Choyke, P. L. Functional MRI in prostate cancer detection. Biomed. Res. Int. 2014, 590638 (2014
48. Symons, J. L., et al. Outcomes of transperineal template-guided prostate biopsy in 409 patients. BJU Int. 112, 585-593 (2013
49. Bellardita, L., et al. How does active surveillance for prostate cancer affect quality of life?. a systematic review. Eur. Urol. 67, 637-645 (2014
50. McIntosh, H. M., et al. Follow up care for men with prostate cancer and the role of primary care: a systematic review of international guidelines. Br. J. Cancer 100, 1852-1860 (2009
51. Dahm, P., Yeung, L. L., Chang, S. S. & Cookson, M. S. A critical review of clinical practice guidelines for the management of clinically localized prostate cancer. J. Urol. 180, 451-459 (2008
52. Wollersheim, H., Burgers, J. & Grol, R. Clinical guidelines to improve patient care. Neth. J. Med. 63, 188-192 (2005
53. Jones, J. & Hunter, D. Consensus methods for medical and health services research. BMJ 311, 376-380 (1995